V
Vinod Pullarkat
Researcher at City of Hope National Medical Center
Publications - 280
Citations - 9132
Vinod Pullarkat is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 37, co-authored 219 publications receiving 6536 citations. Previous affiliations of Vinod Pullarkat include University of Southern California & Biogen Idec.
Papers
More filters
Journal ArticleDOI
Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome
Caroline I. Piatek,Maria E. Vergara-Lluri,Vinod Pullarkat,Imran Siddiqi,Casey O'Connell,Russell K. Brynes,Donald I. Feinstein +6 more
TL;DR: A single-institution, retrospective chart review of patients diagnosed with autoimmune myelofibrosis found the majority of patients with AIMF experience an improvement in cytopenias with immunosuppressive therapy.
Journal ArticleDOI
Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies
Keith W. Pratz,Courtney D. DiNardo,Martha Arellano,Anthony Letai,Michael J. Thirman,Vinod Pullarkat,Gail J. Roboz,Pamela S. Becker,Pamela S. Becker,Wan-Jen Hong,Qi Jiang,John Hayslip,Jalaja Potluri,Daniel A. Pollyea +13 more
TL;DR: Venetoclax in combination with either HMAs or LDAC has led to high rates of early, deep and durable responses in untreated AML patients ineligible for standard induction chemotherapy, suggesting that prior to SCT in patients deemed ineligible for intensive chemotherapy may provide a durable remissions.
Journal ArticleDOI
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)
Se young Han,Krzysztof Mrózek,Jenna M. Voutsinas,Qian Wu,Elizabeth A. Morgan,Hanne Vestergaard,Robert S. Ohgami,Philip M. Kluin,Thomas Kielsgaard Kristensen,Sheeja T. Pullarkat,Michael Boe Møller,Ana Iris Schiefer,Linda B. Baughn,Linda B. Baughn,Young L. Kim,David R. Czuchlewski,Jacobien R. Hilberink,Hans-Peter Horny,Tracy I. George,Tracy I. George,Michelle M Dolan,Nam K. Ku,Cecilia Arana Yi,Vinod Pullarkat,Jessica Kohlschmidt,Amandeep Salhotra,Lori Soma,Lori Soma,Clara D. Bloomfield,Dong Chen,Wolfgang R. Sperr,Guido Marcucci,Christina Cho,Christina Cho,Cem Akin,Jason Gotlib,Sigurd Broesby-Olsen,Melissa L. Larson,Michael A. Linden,H. Joachim Deeg,H. Joachim Deeg,Gregor Hoermann,Gregor Hoermann,Miguel-Angel Perales,Miguel-Angel Perales,Jason L. Hornick,Mark R. Litzow,Ryotaro Nakamura,Daniel J. Weisdorf,Gautam Borthakur,Gerwin Huls,Peter Valent,Celalettin Ustun,Celalettin Ustun,Cecilia C. S. Yeung,Cecilia C. S. Yeung +55 more
TL;DR: In this article, the authors retrospectively analyzed 537 patients with CBF acute myeloid leukemia (AML), focusing on additional cytogenetic aberrations to examine their impact on clinical outcomes.
Journal ArticleDOI
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
Daniel A. Pollyea,Keith W. Pratz,Andrew H. Wei,Vinod Pullarkat,Brian A. Jonas,Christian Recher,Sunil Babu,Andre C. Schuh,Monique Dail,Yan Sun,Jalaja Potluri,Brenda Chyla,Courtney D. DiNardo +12 more
TL;DR: In poor-risk cytogenetics+TP53mut patients, venetoclax+azacitidine improved remission rates but not DoR or OS compared to azac itidine alone, However, in poor- risk cytogenetic patients with AML harboring TP53mut or TP53wt patients,VenetClax + azacItidine resulted in higher remission rates and longer DoR and OS than azacITidine alone.
Journal ArticleDOI
Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data.
TL;DR: How these endpoints are difficult to measure in clinical trials designed to improve platelet counts and minimize bleeding are discussed, in accordance with ethical trial design are discussed.